Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Veterinary Immunology and Immunopathology

Volumn 130, Issue 1-2, 2009, Pages 11-16

  Elders, R C ^a   Baines, S J ^a   Catchpole, B ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Apoptosis; C2; Mast cell tumor; TNFRSF11B; TRAIL

Indexed keywords

CASPASE 3; CASPASE 7; DEATH RECEPTOR; LIPOCORTIN 5; MESSENGER RNA; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LABELING; CELL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG DISEASE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENE SEQUENCE; GENOME ANALYSIS; MASTOCYTOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; TUMOR CELL;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; DOG DISEASES; DOGS; FLOW CYTOMETRY; MASTOCYTOMA; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

CANIS FAMILIARIS;

EID: 67349262746     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.12.023     Document Type: Article

References (47)

1. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
2. Ashkenazi A., and Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118 (2008) 1979-1990
3. Baldwin D., Ramakrishnan L., Gray C., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
4. Belka C., Schmid B., Marini P., Durand E., Rudner J., Faltin H., Bamberg M., Schulze-Osthoff K., and Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20 (2001) 2190-2196
5. Bostock D.E. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br. Vet. J. 142 (1986) 1-19
6. Bostock D.E., Crocker J., Harris K., and Smith P. Nucleolar organizer regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br. J. Cancer 59 (1989) 915-918
7. Brodey R.S. Canine and feline neoplasia. Adv. Vet. Sci. Comp. Med. 14 (1970) 309-354
8. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37 (2007) 101-107
9. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 (1997) 821-830
10. De Toni E.N., Thieme S.E., Herbst A., Behrens A., Stieber P., Jung A., Blum H., Göke B., and Kolligs F.T. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin. Cancer Res. 14 (2008) 4713-4718
11. Downing S., Chien M.B., Kass P.H., Moore P.E., and London C.A. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am. J. Vet. Res. 63 (2002) 1718-1723
12. Finnberg N., Klein-Szanto A.J., and El-Deiry W.S. TRAIL-R deficiency in mice promoted susceptibility to chronic inflammation and tumourigenesis. J. Clin. Invest. 118 (2008) 111-123
13. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
14. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., Iacobucci A., Maclean M., Lo L., Fox N.L., and Oza A.M. A phase 1 study of Mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14 (2008) 3450-3455
15. Hu W.H., Johnson H., and Shu H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-B and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274 (1999) 30603-30610
16. Lazarus S.C., DeVinney R., McCabe L.J., Finkbeiner W.E., Elias D.J., and Gold W.M. Isolated canine mastocytoma cells: propagation and characterization of two cell lines. Am. J. Physiol. 251 (1986) C935-C944
17. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
18. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
19. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., and Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27 (1999) 689-697
20. London C.A., and Seguin B. Mast cell tumors in the dog. Vet. Clin. North Am. Small Anim. Pract. 33 (2003) 473-489
21. Ma Y., Longley B.J., Wang X., Blount J.L., Langley K., and Caughey G.H. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J. Invest. Dermatol. 112 (1999) 165-170
22. Madin S.H., Andriese P.C., and Darby N.B. The in vitro cultivation of tissues of domestic and laboratory animals. Am. J. Vet. Res. 18 (1957) 146-156
23. Meng R.D., McDonald III E.R., Sheikh M.S., Fornance Jr. A.J., and El-Deiry W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1 (2000) 130-144
24. O'Keefe D.A., Couto C.G., Burke-Schwartz C., and Jacobs R.M. Systemic mastocytosis in 16 dogs. J. Vet. Intern. Med. 1 (1987) 75-80
25. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
26. Pan G., Ni J., Yu G., Wei Y.F., and Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett. 424 (1998) 41-45
27. Patnaik A.K., Ehler W.J., and MacEwen E.G. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet. Pathol. 21 (1984) 469-474
28. Peters J.A. Canine mastocytoma: excess risk as related to ancestry. J. Natl. Cancer Inst. 42 (1969) 435-443
29. Pinelli E., van der Kaaij S.Y., Slappendel R., Fragio C., Ruitenberg E.J., Bernadina W., and Rutten V.P. Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction. Vet. Immunol. Immunopathol. 69 (1999) 121-126
30. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
31. Priester W.A. Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J. Natl. Cancer Inst. 50 (1973) 457-466
32. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., and El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 24 (2004) 8541-8555
33. Rong S., Cai J.H., and Andrews J. Cloning and apoptosis-inducing activities of canine and feline TRAIL. Mol. Cancer Ther. 7 (2008) 2181-2191
34. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004) 1655-1664
35. Rothwell T.L., Howlett C.R., Middleton D.J., Griffiths D.A., and Duff B.C. Skin neoplasms of dogs in Sydney. Aust. Vet. J. 64 (1987) 161-164
36. Schneider P., Bodmer J.L., Thome M., Hofmann K., Holler N., and Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 416 (1997) 329-334
37. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
38. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
39. Spee B., Jonkers M.D., Arends B., Rutteman G.R., Rothuizen J., and Penning L.C. Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer 5 (2006) 34
40. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
41. Webster J.D., Kiupel M., and Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 6 (2006) 85
42. Wen J., Ramadevi N., Nguyen D., Perkins C., Worthington E., and Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96 (2000) 3900-3906
43. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., and Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
44. Woo K.M., Choi Y., Ko S.-H., Ko J.S., Oh K.-O., and Kim K.-K. Osteoprotegerin is present on the membranes of osteoclasts isolated from mouse long bones. Exp. Mol. Med. 34 (2002) 347-352
45. Yun T.J., Chaudhary P.M., Shu G.L., Frazer J.K., Ewings M.K., Schwartz S.M., Pascual V., Hood L.E., and Clark E.A. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161 (1998) 6113-6121
46. Zemke D., Yamini B., and Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet. Pathol. 39 (2002) 529-535
47. Zerafa N., Westwood J.A., Cretney E., Mitchell S., Waring P., Iezzi M., and Smyth M.J. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175 (2005) 5586-5590